


Olodanrigan

Cat. No.:	HY-13106		
CAS No.:	1316755-16-4		
Molecular Formula:	C ₃₂ H ₂₉ NO ₅		
Molecular Weight:	507.58		
Target:	Angiotensin Receptor		
Pathway:	GPCR/G Protein		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 200 mg/mL (394.03 mM; Need ultrasonic)
 H₂O : < 0.1 mg/mL (insoluble)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	1.9701 mL	9.8507 mL	19.7013 mL
	5 mM	0.3940 mL	1.9701 mL	3.9403 mL
	10 mM	0.1970 mL	0.9851 mL	1.9701 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 5 mg/mL (9.85 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Olodanrigan (EMA401) is a highly selective, orally active, peripherally restricted angiotensin II type 2 receptor (AT2R) antagonist. It is under development as a neuropathic pain therapeutic agent. Olodanrigan (EMA401) analgesic action appears to involve inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons^{[1][2][3][4]}.

IC₅₀ & Target

AT2 Receptor

In Vivo

EMA401 (10 mg/kg; p.o.) results in a significant attenuation of theta power and increase in paw withdrawal latencies (PWL) in rats at day 14 after chronic constriction injury (CCI)^[4].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Radiother Oncol. 2024 Dec 19:110686.
- J Pharmacol Sci. 146 (2021) 121-124.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Rice AS et al. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. *Lancet*. 2014 May 10;383(9929):1637-47.
- [2]. Anand U et al. Mechanisms underlying clinical efficacy of Angiotensin II type 2 receptor (AT2R) antagonist EMA401 in neuropathic pain: clinical tissue and in vitro studies. *Mol Pain*. 2015 Jun 26;11:38.
- [3]. Suguru Koyama, et al. An Electroencephalography Bioassay for Preclinical Testing of Analgesic Efficacy.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA